Real-World Weight Loss on Ozempic and Wegovy: The 5-12% You Might Get Versus the 15% in the Trials

Semaglutide's Phase 3 trial for weight loss (STEP-1) reported that people who took the drug lost 14.9% of their body weight on average over 68 weeks. That number is the one that anchors most of the marketing, most of the news coverage, and most of the expectations that new patients bring to their first prescription.

Real-world data tells a different story. Registry studies and insurance claims analyses that have followed thousands of people on Wegovy or Ozempic outside of trial settings report average weight loss in the range of 5.9% to 12% at 6 to 12 months. Cleveland Clinic research published in 2025 confirmed the pattern: injectable obesity medications produce smaller weight loss in a real-world setting than in randomized clinical trials.

A 5 to 9 percentage point gap between trial results and real-world results is a real thing, and it matters. For a 250-pound person, the difference between 15% and 8% is roughly 17 pounds. Setting expectations correctly at the start of therapy makes the difference between a patient who stays on the drug and gets a real result, and a patient who quits within a few months disappointed.

This piece walks through what the trials actually measured, what real-world data shows, why the gap exists (it is not because the drug works differently in the real world; it is because trial conditions and real conditions differ substantially), who tends to respond better, and what happens when people stop the drug.

STEP-1 was the Phase 3 registrational trial that supported the FDA approval of semaglutide 2.4 mg once weekly for chronic weight management under the Wegovy brand. Understanding what STEP-1 actually measured is important context for interpreting the real-world numbers.

Trial design. 1,961 adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity. Randomized 2:1 to semaglutide 2.4 mg once weekly subcutaneous injection or placebo, both alongside a lifestyle intervention (reduced-calorie diet plus increased physical activity). Duration: 68 weeks.

Result. Mean body weight change was −14.9% for semaglutide versus −2.4% for placebo. Roughly 86% of the semaglutide group achieved at least 5% weight loss; 69% achieved at least 10%; 50% achieved at least 15%; 32% achieved at least 20%.

Trial conditions that shape the number. Three things about STEP-1 shape the 14.9% average and are usually not visible in real-world use.

First, adherence in a trial is much higher than adherence in real-world care. STEP-1 participants received free drug, monthly check-ins with the study team, standardized dose-escalation coaching, and pharmacy support to prevent dose gaps. Real-world patients pay out-of-pocket or navigate insurance, may skip doses for cost reasons, may pause for GI side effects without immediate coaching support, and may not have monthly check-ins with a prescriber.

Second, the lifestyle intervention in STEP-1 was substantial. Every participant, drug and placebo, received counseling to follow a reduced-calorie diet (500 kcal/day below maintenance) plus 150+ minutes per week of moderate physical activity. Real-world patients frequently do not receive this lifestyle intervention and get much less structured support.

Third, STEP-1 measured weight loss on-treatment. Patients who discontinued the drug during the trial for any reason were excluded from the primary efficacy analysis in the original protocol (the on-treatment analysis; treatment-policy estimand analyses were reported separately and produced slightly lower numbers). Real-world claims analyses do not have that filter; they measure weight change across everyone who filled a prescription, including patients who quit after a few months.

Several large real-world studies have measured weight loss on semaglutide 2.4 mg (Wegovy) or semaglutide 1.0-2.0 mg (Ozempic, used off-label for weight loss) in claims databases and clinical registries. Consistent findings:

Cleveland Clinic 2025 study. Retrospective analysis of ~1,400 patients on semaglutide 2.4 mg or 1.0 mg for weight loss over 12 months. Mean weight loss at 12 months was 5.9% for the 1.0 mg dose group and roughly 9-10% for the 2.4 mg dose group. The gap versus STEP-1's 14.9% at 68 weeks is real and roughly consistent with adherence patterns.

WeGoTogether digital-support registry. Adults initiating semaglutide 2.4 mg enrolled in a Novo Nordisk digital self-support application. Mean weight loss at 6 months was around 8-9% and continued gaining through 12 months, closer to trial trajectory but still below.

Truveta / Epic real-world EHR analyses. Multiple analyses of electronic health record data across large US healthcare systems have documented mean weight loss in the 7% to 11% range at 6 to 12 months for GLP-1 users, with substantial variability by drug, dose, and adherence pattern.

Claims-based studies. Analyses using pharmacy claims to identify patients who filled a semaglutide or tirzepatide prescription for weight loss have consistently found weight loss in the 5% to 9% range at 12 months when the analysis includes discontinuers.

The headline finding across studies: real-world weight loss on semaglutide 2.4 mg averages somewhere between 5.9% and 12%. The upper end approaches trial results when adherence is high and follow-up is structured; the lower end reflects populations with more dose gaps, more discontinuation, and less structured lifestyle support.

The 5-9 percentage point gap between STEP-1's 14.9% and real-world 5.9-12% is not a mystery. Four factors explain most of it.

Adherence, especially dose gaps. GLP-1 therapy works through steady exposure. When patients skip weeks or extend the interval between doses (whether from cost, shortage, side effects, or life disruption), the appetite-suppression effect fades and weight loss slows or reverses. Real-world claims data shows that a substantial fraction of Wegovy patients have gaps of 30+ days between refills within the first 12 months. Trial patients rarely have such gaps.

Discontinuation within the first year. Real-world discontinuation rates on Wegovy are high. Various studies report 20% to 30% of patients quitting within 6 months and roughly 40-50% quitting within 12 months. Reasons: cost (out-of-pocket at $1,349/month before insurance and manufacturer coupons), GI side effects (nausea, vomiting, constipation), plateau frustration, and the return of hunger when patients try to reduce dose or stop. Every discontinuation drags down the population-average number.

Titration challenges and staying at lower doses. STEP-1 titrated semaglutide to the full 2.4 mg dose over 16 weeks according to a fixed schedule. Real-world patients often stay at lower doses (0.5 mg, 1.0 mg, 1.7 mg) longer because of GI intolerance or supply issues. Sub-maximal dose = sub-maximal effect. If half your population never reaches 2.4 mg, the average weight loss will be well below the 14.9% observed in a population that all reached the target dose.

Lifestyle-intervention absence. STEP-1 built in a 500 kcal/day deficit and 150+ min/week of exercise counseling. Most real-world Wegovy prescriptions come without that structured support. A drug that reduces appetite by 30% still produces less weight loss if the patient replaces the calories with different foods or maintains sedentary activity levels. Some real-world programs (Hims, Ro, WeightWatchers Clinic, Noom) do provide lifestyle coaching; adherence in those programs generally lands closer to trial numbers, though still below.

The consistent conclusion across studies: the drug works. The trial number is not misleading in a technical sense. The real-world number is lower because the real world provides less scaffolding around the drug than the trial did.

Individual response to semaglutide varies substantially. Some patients on the drug lose more than 25%; some lose less than 5%. Predictors of stronger response, from published real-world analyses:

Higher baseline BMI. Patients starting at BMI 40+ tend to lose more absolute pounds, though the percentage loss can be similar.

Reaching the full 2.4 mg dose. Patients who titrate successfully to 2.4 mg maintenance have substantially better outcomes than patients who stall at 1.0 mg or 1.7 mg.

Consistent adherence in the first 12 weeks. Patients who fill every scheduled prescription in months 1 through 3 tend to build the plateau-avoiding trajectory that runs through month 12; patients with early gaps often drift.

Structured lifestyle support. Patients enrolled in coaching, digital support, or dietary counseling programs consistently outperform patients on drug alone.

Fewer GI side effects. Patients who tolerate the drug well at each dose step tend to reach 2.4 mg and stay there; patients with severe GI issues often stall at lower doses.

Younger age. Patients under 45 tend to lose slightly more than patients over 65, though older patients still lose substantial weight when they tolerate the drug.

Female sex. Multiple studies find women lose slightly more percentage weight than men on semaglutide, though the reason is not fully understood.

Predictors of weaker response: high baseline hunger scores, prior weight-loss drug failures, uncontrolled type 2 diabetes (drug is less effective in patients with significant insulin resistance), and specific medications (some antipsychotics and antidepressants counteract the appetite effect).

Any real conversation about GLP-1 weight loss has to include the discontinuation question. The trial and real-world data on this are consistent.

Weight regain is common. STEP-4, a controlled discontinuation trial, showed that patients who stopped semaglutide after 20 weeks regained approximately two-thirds of their lost weight over the following 48 weeks, even with continued lifestyle intervention. STEP-1 extension data shows similar regain patterns when patients discontinue.

Real-world regain is variable. A large real-world study of nearly 8,000 patients who discontinued GLP-1 therapy found that most managed to keep the weight off or continue losing by restarting treatment, switching medications, or making substantial lifestyle changes. Not everyone regains everything. But most patients who discontinue and do nothing else regain substantially.

The biology behind regain. GLP-1 receptor agonists reduce appetite by activating the receptor. When the drug is stopped, the appetite-suppression effect ends within days to weeks (matched to the drug's half-life; semaglutide's half-life is about one week, so effect fades over several weeks). Hunger returns. Without a habit change to work with the drug's effect while it was active, patients tend to return to prior eating patterns.

Practical implication. GLP-1 therapy for chronic weight management should be evaluated as a chronic therapy, like antihypertensives or statins, not as a temporary intervention. Patients who plan to use the drug for 3-6 months and then stop should expect to regain most of the lost weight. Patients who plan to stay on the drug indefinitely should factor cost, side-effect tolerance, and long-term adherence into the decision from the start.

Off-label uses of low-dose semaglutide for shorter courses (10-30 pounds, then discontinuation) exist widely in wellness and telehealth contexts. The published evidence base for those protocols is thin. The regain question applies regardless of the initial course length.

For someone considering starting Wegovy or Ozempic (off-label for weight loss), a few practical takeaways from the trial-versus-real-world data.

Set expectations near the real-world range, not the trial average. Expecting 15% because that is the number in the ads is likely to produce disappointment. Expecting 7-12% at 6-12 months with consistent adherence is closer to the median real-world outcome. Some individuals will do better; some will do worse.

Adherence is not optional. The single strongest predictor of good outcomes across every real-world study is consistent weekly dosing without gaps. Cost, supply, and side-effect management all need to work in the patient's real life for the drug to produce trial-like results.

Titration to 2.4 mg matters. Patients who stall at 1.0 mg or 1.7 mg for cost or tolerability reasons should discuss whether that is a temporary hold (with plan to titrate later) or an accepted lower-efficacy maintenance dose. Both are valid choices; the outcomes just differ.

Lifestyle support boosts results. A drug plus a diet-and-exercise plan produces meaningfully better outcomes than a drug alone. Digital coaching apps, in-person nutrition counseling, structured exercise programs, and support groups all show measurable additional weight loss on top of the drug effect. The drug is a tool that works better when paired with the other tools.

Plan for the maintenance phase. Weight loss on GLP-1s tends to plateau by month 12-18. The next question is: stay on the drug indefinitely at the current dose, taper to a lower maintenance dose, or discontinue. Each path has different trade-offs. Discussing this with the prescriber before month 12 avoids surprises and lets the patient plan cost, tolerability, and follow-up on a longer horizon.

Prescribing decisions belong with a clinician. This piece describes population-level averages. Individual response varies widely, and treatment decisions involve medical history, insurance coverage, tolerability, and personal preferences that a class-level summary cannot address.

Semaglutide 2.4 mg (Wegovy) delivers 14.9% mean weight loss at 68 weeks in the STEP-1 trial. Real-world registry and claims analyses report 5.9% to 12% at 6 to 12 months for the same drug in the same doses. The gap is real, and it is driven by adherence gaps, discontinuation, sub-maximal dosing, and the absence of structured lifestyle support that trial participants received automatically.

The drug works. The real-world number is lower because the real world provides less structure around the drug than the trial did.

For patients starting semaglutide today, setting expectations around 7-12% at 12 months rather than around 15% is the honest place to start. Individual responses vary widely, and adherence, titration success, and lifestyle support all determine where in the range a specific patient lands. Tirzepatide (Zepbound, Mounjaro) generally produces slightly higher weight loss in both trials and real-world use, with roughly similar trial-versus-real-world gaps. Retatrutide, if approved as expected in 2027-2028, will bring higher trial numbers still (28.7% in TRIUMPH-1), and the same real-world gap dynamics will apply.

Weight regain after discontinuation is common in the absence of continued treatment or substantial lifestyle change. GLP-1 therapy for weight management is chronic therapy. Planning for that reality at the start of therapy makes the whole trajectory more predictable.